FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2Qin Ryan, Richard Pazdur, Martin H. Cohen et al.|The Oncologist|2008Cited by 310